NCT04497389View on ClinicalTrials.gov

Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

August 2, 2022

Study Completion Date

February 15, 2023

Conditions
SARS CoV-2
Interventions
BIOLOGICAL

Human Amniotic Fluid

Patients will receive 10ml intravenous hAF each day for 5 consecutive days.

Trial Locations (1)

84132

University of Utah Health, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT04497389 - Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients | Biotech Hunter | Biotech Hunter